US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.23

-0.2400-5.37%

Post-market: 4.300.0683+1.61%19:30 EDT

Volume:819.74K

Turnover:3.49M

Market Cap:132.36M

PE:-1.02

High:4.44

Open:4.44

Low:4.21

Close:4.47

52wk High:50.40

52wk Low:4.21

Shares:31.29M

Float Shares:18.39M

Volume Ratio:1.13

T/O Rate:4.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.60

PE(LYR):-1.48

Loading ...

Overview Company News Filings

Alterity Therapeutics Seeks Quotation for New ASX Shares

Top Oruka Therapeutics Insiders Quietly Cash Out in Major Stock Moves

Decoy Therapeutics Shareholders Approve Key Capital Structure Changes

Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

MT Newswires Live

Tempest Therapeutics Announces New Private Warrant Financing

Coya Therapeutics Price Target Maintained with a $16.00/Share by BTIG

Summit Therapeutics Highlights Positive Ivonescimab Phase III Survival Data

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Neurizon Therapeutics Redeems 1 Million Convertible Notes Without Conversion

Immunology-Focused Biotech Electra Therapeutics Sets IPO Price Range at $14-$16 Per Share, Eyeing $325 Million Raise

Prescient Therapeutics Extends Securities Purchase Plan Deadline

Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%

MT Newswires Live

Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy

Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug

Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit

MT Newswires Live

Turn Therapeutics Price Target Announced at $10.00/Share by WBB Securities

Larimar Therapeutics assumed with an Outperform at Leerink

Summit Therapeutics Showcases Promising Ivonescimab Survival Data

Electra Therapeutics Sets IPO at 21.7 Million Shares Priced at $14-$16 Each

Whitehawk Therapeutics presents PTK7 data at WCLC 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/LENZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.23,"timestamp":1789502400000,"preClose":4.47,"halted":0,"volume":819744,"hourTrading":{"tag":"盘后","latestPrice":4.2983,"preClose":4.23,"latestTime":"19:30 EDT","volume":15901,"amount":67483.3442,"timestamp":1789515006325,"change":0.0683,"changeRate":0.016147,"amplitude":0.016147},"delay":0,"changeRate":-0.05369127516778509,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Not Yet Opened","change":-0.24,"latestTime":"09-15 16:00:00 EDT","open":4.44,"high":4.44,"low":4.205,"amount":3490942.944288,"amplitude":0.052573,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.47,"preHourTrading":{"tag":"盘前","latestPrice":4.54,"preClose":4.47,"latestTime":"08:23 EDT","volume":278,"amount":1243.870134,"timestamp":1789475036174,"change":0.07,"changeRate":0.01566,"amplitude":0.040268},"postHourTrading":{"tag":"盘后","latestPrice":4.2983,"preClose":4.23,"latestTime":"19:30 EDT","volume":15901,"amount":67483.3442,"timestamp":1789515006325,"change":0.0683,"changeRate":0.016147,"amplitude":0.016147},"volumeRatio":1.125925,"impliedVol":3.2046,"impliedVolPercentile":0.952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":1.125925,"shares":31289969,"dividePrice":0,"high":4.44,"amplitude":0.052573,"preClose":4.47,"low":4.205,"week52Low":4.205,"pbRate":"0.60","psRate":"6.16","week52High":50.4,"institutionHeld":0,"latestPrice":4.23,"eps":-4.13,"divideRate":0,"volume":819744,"delay":0,"ttmEps":-4.13,"open":4.44,"prevYearClose":16,"prevWeekClose":4.52,"prevMonthClose":5.21,"prevQuarterClose":5.68,"fiveDayClose":5.33,"twentyDayClose":4.79,"sixtyDayClose":6.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-09-14","current":-1.024213,"percent":1,"low":-26.69966,"twenty":-16.221552,"median":-9.727905,"eighty":-5.201783,"high":-1.127125,"avg":-10.488955,"sd":6.209374,"marketCap":142019950},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-14","current":-1.127125,"twenty":-16.221552,"median":-9.727905,"eighty":-5.201783,"marketCap":142019950}],"updateTime":1789544528981},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667679049","title":"Alterity Therapeutics Seeks Quotation for New ASX Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2667679049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667679049?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:43","pubTimestamp":1789526623,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics has applied for quotation of 50,000 new ordinary fully paid shares ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-seeks-quotation-for-new-asx-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-seeks-quotation-for-new-asx-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667197676","title":"Top Oruka Therapeutics Insiders Quietly Cash Out in Major Stock Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2667197676","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667197676?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:01","pubTimestamp":1789524066,"startTime":"0","endTime":"0","summary":"New insider activity at Oruka Therapeutics ( ($ORKA) ) has taken place on September 15, 2026. Oruka Therapeutics has seen notable insider activity,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-oruka-therapeutics-insiders-quietly-cash-out-in-major-stock-moves-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-oruka-therapeutics-insiders-quietly-cash-out-in-major-stock-moves-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667627509","title":"Decoy Therapeutics Shareholders Approve Key Capital Structure Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2667627509","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667627509?lang=en_us&edition=fundamental","pubTime":"2026-09-16 05:54","pubTimestamp":1789509263,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics ( ($DCOY) ) just unveiled an announcement. On September 14, 2026, Decoy Therapeutics Inc. held a special meeting of stockholders...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/decoy-therapeutics-shareholders-approve-key-capital-structure-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/decoy-therapeutics-shareholders-approve-key-capital-structure-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667627808","title":"Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang","url":"https://stock-news.laohu8.com/highlight/detail?id=2667627808","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667627808?lang=en_us&edition=fundamental","pubTime":"2026-09-16 05:45","pubTimestamp":1789508730,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.Tempest shares rose 35% in after-hours trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TPST","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667622346","title":"Tempest Therapeutics Announces New Private Warrant Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667622346","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667622346?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:32","pubTimestamp":1789504343,"startTime":"0","endTime":"0","summary":"The latest update is out from Tempest Therapeutics ( ($TPST) ). On September 11, 2026, Tempest Therapeutics entered into a securities purchase agre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-new-private-warrant-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-new-private-warrant-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667662694","title":"Coya Therapeutics Price Target Maintained with a $16.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2667662694","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667662694?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:22","pubTimestamp":1789489320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COYA/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667640680","title":"Summit Therapeutics Highlights Positive Ivonescimab Phase III Survival Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2667640680","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667640680?lang=en_us&edition=fundamental","pubTime":"2026-09-15 21:20","pubTimestamp":1789478440,"startTime":"0","endTime":"0","summary":"Summit Therapeutics ( ($SMMT) ) has issued an update. On September 15, 2026, Summit reported updated overall survival data from its global Phase II...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-highlights-positive-ivonescimab-phase-iii-survival-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-highlights-positive-ivonescimab-phase-iii-survival-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667564210","title":"Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2667564210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667564210?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3362020/0/en/allarity-therapeutics-granted-japanese-patent-for-stenoparib-drp-companion-diagnostic-further-strengthening-stenoparib-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JPO","BK4539","LENZ","BK4007","JPMO","USRD","ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667102676","title":"Neurizon Therapeutics Redeems 1 Million Convertible Notes Without Conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2667102676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667102676?lang=en_us&edition=fundamental","pubTime":"2026-09-15 16:28","pubTimestamp":1789460912,"startTime":"0","endTime":"0","summary":"Pharmaust Limited ( ($AU:NUZ) ) just unveiled an announcement. Neurizon Therapeutics Limited has announced the cessation of 1,000,000 NUZAA convert...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurizon-therapeutics-redeems-1-million-convertible-notes-without-conversion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurizon-therapeutics-redeems-1-million-convertible-notes-without-conversion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199621546","title":"Immunology-Focused Biotech Electra Therapeutics Sets IPO Price Range at $14-$16 Per Share, Eyeing $325 Million Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=1199621546","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199621546?lang=en_us&edition=fundamental","pubTime":"2026-09-15 15:28","pubTimestamp":1789457298,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology firm Electra Therapeutics, which is advancing targeted SIRP antibody therapies for immune disorders and oncology, unveiled the terms for its initial public offering on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEIH","MEDX","AGNG","LNGR","LENZ","IPOS","SYNB","ETRA","UUP","BK4588","IBBJ","BK4539","XBI","UDN","BK4139","BK4007","BK4585","159837","GDOC","BK4581","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667316690","title":"Prescient Therapeutics Extends Securities Purchase Plan Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2667316690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667316690?lang=en_us&edition=fundamental","pubTime":"2026-09-15 10:02","pubTimestamp":1789437732,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics Limited ( ($AU:PTX) ) just unveiled an update. Prescient Therapeutics Limited, an ASX-listed biotechnology company trading u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-extends-securities-purchase-plan-deadline-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-extends-securities-purchase-plan-deadline-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FHLC","SYNB","BK4007","LENZ","DARP","BBP","IEIH","XT","BK4585","BK4539","IBB","JDOC","BK4588","LNGR","FWD","AGNG","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697967","title":"Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697967","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667697967?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:30","pubTimestamp":1789435858,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  and the Australia New Zealand Gynaecological Oncology Group  have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.The study is expected to enroll around 26 patients at selected sites across Australia and New Zealand, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.The company's shares rose 4% in recent Tuesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4007","BK7067","ATX.AU","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667724696","title":"Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667724696","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667724696?lang=en_us&edition=fundamental","pubTime":"2026-09-15 05:45","pubTimestamp":1789422312,"startTime":"0","endTime":"0","summary":"Quince Therapeutics ( ($QNCX) ) has issued an announcement. On September 8, 2026, Quince Therapeutics completed the sale of all equity in its Itali...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-divests-italian-subsidiary-refocuses-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-divests-italian-subsidiary-refocuses-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667957316","title":"Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667957316","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667957316?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:48","pubTimestamp":1789418880,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics said a phase 1 study for a lung disease treatment showed a reduction in a target protein, supporting the launch of a phase 2 study.The clinical-stage biopharmaceutical company said that a twice-daily 4.5mg dose of AGMB-447, a treatment for idiopathic pulmonary fibrosis, had a more than 50% reduction of pSMAD3 proteins in lung fluid cells.The dosage also had a generally favorable safety and tolerability profile, the company said. A 6mg twice-daily dose also evaluated in the study had a higher incidence of adverse events but no new specific safety signals.\"We believe that by blocking the TGF<BETA>/ALK5 pathway locally in the lung, AGMB-447 has the potential to offer a potent anti-fibrotic therapy to IPF patients,\" Chief Medical Officer Philippe Wiesel said. \"The extensive data collected in our broad Phase 1 program supports the initiation of our Phase 2 INSPIRIA study later this year.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667980906","title":"Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2667980906","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667980906?lang=en_us&edition=fundamental","pubTime":"2026-09-15 03:09","pubTimestamp":1789412997,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  shares rose approximately 5% in Monday trading, a day after the company said its partner Akeso reported updated data, including overall survival, from phase III HARMONi-2 trial of investigational bispecific antibody ivonescimab, showing a 27% reduction in the risk of death compared with pembrolizumab.The trial conducted in China evaluates ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer, whose tumors have positive PD-L1 expression, the company said.The HARMONi-2 data will be presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer in Seoul, Korea on Tuesday, the company added.Ivonescimab is approved and commercially available for indications in NSCLC in China but remains investigational and has not been approved in Summit's license territories, including the US and Europe, according to a statement.Price: 18.42, Change: +0.87, Per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SMMT","BK4139","BK4007","BK4539","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667674736","title":"Turn Therapeutics Price Target Announced at $10.00/Share by WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2667674736","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667674736?lang=en_us&edition=fundamental","pubTime":"2026-09-15 00:21","pubTimestamp":1789402860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TTRX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667166222","title":"Larimar Therapeutics assumed with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2667166222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667166222?lang=en_us&edition=fundamental","pubTime":"2026-09-14 23:15","pubTimestamp":1789398914,"startTime":"0","endTime":"0","summary":"Leerink analyst Basma Radwan assumed coverage of Larimar Therapeutics (LRMR) with an Outperform rating and a price target of $13, up from $12. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-assumed-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-assumed-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667669859","title":"Summit Therapeutics Showcases Promising Ivonescimab Survival Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2667669859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667669859?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:57","pubTimestamp":1789390669,"startTime":"0","endTime":"0","summary":"An update from Summit Therapeutics ( ($SMMT) ) is now available. On September 13, 2026, Summit Therapeutics highlighted new overall survival data f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-showcases-promising-ivonescimab-survival-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-showcases-promising-ivonescimab-survival-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667571296","title":"Electra Therapeutics Sets IPO at 21.7 Million Shares Priced at $14-$16 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2667571296","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667571296?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:20","pubTimestamp":1789381200,"startTime":"0","endTime":"0","summary":"Clinical-stage biopharmaceutical company Electra Therapeutics plans to sell nearly 21.7 million shares at between $14 and $16 apiece in its initial public offering.At the $15 midpoint of that price range, the South San Francisco, Calif., company said it expects net proceeds of about $296.6 million, or roughly $341.9 million if the underwriters exercise an option to buy an additional 3.25 million shares.Electra, which focuses on treatments for immune-mediated diseases and cancer, said it expects the proceeds, coupled with its existing resources, will be sufficient to fund its projected operating expenses and capital-spending needs into 2029.Electra said it would have about 60.4 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of around $905 million at the $15-a-share pricing midpoint.The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ETRA.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KCE","BK4539","IPOS","LENZ","FRHC","REDS","BK4139","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652864","title":"Whitehawk Therapeutics presents PTK7 data at WCLC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667652864?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:40","pubTimestamp":1789378822,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics (WHWK) announced the presentation of two real-world analyses supporting protein tyrosine kinase 7, or PTK7, as a durable and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-ptk7-data-at-wclc-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-ptk7-data-at-wclc-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","WHWK","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}